Biotech Active Runners: Illumina, Inc. (NASDAQ:ILMN), Ariad Pharmaceuticals (NASDAQ:ARIA), Amgen, Inc. (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD)

Illumina Inc. (NASDAQ:ILMN) reported first-quarter 2014 adjusted earnings per share (EPS) of 53 cents, breezing past the Zacks Consensus Estimate of 44 cents. Earnings also exceeded the year-ago quarter figure by 15.2%. Illumina, Inc. (NASDAQ:ILMN) shares after opening at $157.51 moved to $158.50 on last trade day and at the end of the day closed at $153.69. Company price to sales ratio in past twelve months was calculated as 13.88 and price to cash ratio as 16.93. Illumina, Inc. (NASDAQ:ILMN) showed a positive weekly performance of 17.28%.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014, before the market opens. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -3.72% in last trading session and ended the day on $7.50. ARIA return on equity ratio is recorded as -98.50% and its return on assets is -65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) yearly performance is -59.70%.

Amgen Inc. (NASDAQ:AMGN) dropped 2.9 percent after sales for its best-selling arthritis drug missed analysts’ estimates. Amgen, Inc. (NASDAQ:AMGN) shares moved down -5.02% in last trading session and was closed at $113.32, while trading in range of $111.51 – $116.45. Amgen, Inc. (NASDAQ:AMGN) year to date (YTD) performance is -0.16%.

Gilead Sciences Inc. (NASDAQ:GILD) overwhelmed sales estimates for its new blockbuster hepatitis C pill in what analysts called the biggest drug start ever. Gilead Sciences, Inc. (NASDAQ:GILD) weekly performance is 8.35%. On last trading day company shares ended up $73.86. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is -3.35%. Analysts mean target price for the company is $97.67.